Trial Profile

A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer NOX-E36 in patients with type 2 diabetes mellitus and albuminuria.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emapticap pegol (Primary)
Indications Diabetic nephropathies; Type 2 diabetes mellitus
Focus Proof of concept; Therapeutic Use
Sponsors NOXXON Pharma AG

Most Recent Events

01 Feb 2017 Results published in the Nephrology Dialysis Transplantation.
27 Apr 2016 Results published in the Nephrology Dialysis Transplantation
09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com